gemcitabine-glucose glycoconjugate 23

gemcitabine-glucose glycoconjugate 23 is an experimental **small-molecule prodrug** that links gemcitabine to glucose through a **redox-reactive disulfide linker** attached via the **N4 position of cytosine**. It was reported in preclinical research as a strategy to exploit **glucose transporter-mediated uptake**, particularly in tumor cells with elevated **GLUT1** expression, and was explored in prostate cancer models including **castration-resistant prostate cancer**. After cellular uptake and intracellular reduction/cleavage, the conjugate is intended to release gemcitabine activity, ultimately inhibiting **DNA synthesis** through gemcitabine's active metabolites. In vitro, the compound showed greater toxicity/efficacy in **androgen-insensitive PC3** prostate cancer cells than in **LNCaP** cells, consistent with a GLUT1-linked uptake hypothesis.

Other names

glucose-gemcitabine glycoconjugate 23gemcitabine-glucose hybridnovel glucose-gemcitabine glycoconjugate